Biotechnology Index

Biotechnology Index

A group of NASDAQ-listed companies designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The NASDAQ Biotechnology Index (BI) is calculated under a modified capitalisation-weighted methodology.

The BI currently includes Affymetrix, Amgen, Applera Corp-Celera Genomics Group, Biogen, Cephalon, Chiron, COR Therapeutics, Genzyme Corporation, Genentech Inc, Gilead Sciences, Human Genome Sciences, IIDEC Pharmaceuticals, Immunex Corporation, Medimmune, Millennium Pharmaceuticals, Protein Design Labs and Vertex Pharmaceuticals.
Mentioned in ?
References in periodicals archive ?
M2 PHARMA-December 19, 2017-GlycoMimetics to Join NASDAQ Biotechnology Index
Anacor gave one of the biggest boosts to the Nasdaq Biotechnology index, which gained some 3 percent.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced that it has been selected for addition to the NASDAQ Biotechnology Index effective Monday, December 21, 2015.
Even with the recent downturn, the NASDAQ Biotechnology Index (IBB) has increased 250% in the past five years.
The Nasdaq Biotechnology Index is a modified capitalization-weighted index that includes Nasdaq-listed companies classified as either biotechnology or pharmaceutical.
After a year of remarkable gains--accentuated by a near-record number of initial public offerings (IPOs) and 61 percent rise in the Nasdaq Biotechnology Index (the gain is more than double the S&P 500's 26 percent growth in 2013)--biotech stocks have significantly lost their luster.
The Nasdaq biotechnology index fell seven per cent for the week.
Biotechnology companies in particular had a standout 2013, with the Nasdaq Biotechnology Index gaining 66 per cent, topping a 30 per cent increase for the Standard & Poor's 500, and closing on Thursday at a record high of 2,449.
M2 EQUITYBITES-December 27, 2013-bluebird bio added to the Nasdaq Biotechnology Index
The firm cites the iShares NASDAQ biotechnology Index, the SPDR S&P Biotech ETF and the First Trust AMEX biotechnology Index ETF, which have all gained over 20% in the past year and outperformed the broader markets by a good margin.
The ETFs seek to provide 200 per cent or -200 per cent of the return of the NASDAQ Biotechnology Index for a single day.
8) Moreover, from 1995 to 2005, the annual returns for the NASDAQ Biotechnology Index and the AMEX Biotechnology Index averaged just over 20 per cent, compared to the annual returns for the S&P 500 Index, the Dow Jones Industrial Average and the NASDAQ Composite averaging just under 10 per cent.

Full browser ?